Oxaliplatin
Extranodal Nasal NK/T Cell Lymphoma
Explore 50 assets in Extranodal Nasal NK/T Cell Lymphoma →Floatz Rating
BB65/100
Confidence
Indicative
Sponsor
CStone Pharmaceuticals
Modality
Small molecule
Development Phase
Phase 3
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
55Moderate confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT05700448CT.gov Study of Sugemalimab (or Placebo) Plus PGemOx Regimen in Participants With Extranodal NK/T-Cell Lymphoma | — | Not Yet Recruiting | — | — | — |
NCT07554482CT.gov Selinexor Combined With Reduced-Dose Radiotherapy For Early-Stage Extranodal NK/T-Cell Lymphoma | — | Not Yet Recruiting | — | — | — |
NCT05254899CT.gov Anti-PD-1 Antibody and P-GEMOX Chemotherapy Combined With Radiotherapy in High-risk Early-Stage ENKTL | — | Unknown | — | — | — |
NCT04365036CT.gov A Multicenter, Phase 3, Randomized Trial of Sequencial Chemoradiotherapy with or Without Toripalimab (PD-1 Antibody) in Newly Diagnosed Early-Stage Extranodal Natural Killer/T Cell Lymphoma, Nasal Type (ENKTL) | — | Recruiting | — | — | — |
NCT04127227CT.gov Sintilimab With P-GemOx Regimen for Newly Diagnosed Advanced Extranodal Natural Killer/T-cell Lymphoma, Nasal Type | — | Active Not Recruiting | — | — | — |
NCT01921790CT.gov Avastin+ GemAOD As First-Line Treatment in NK/T Cell Lymphoma | — | Unknown | — | — | — |
NCT02085655CT.gov PEG-ASP+Gemox Regimen and Thalidomide for NK/T Lymphoma | — | Unknown | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
95Indicative
Detailed axis rationale is planned and will be published soon.
Same indication · Extranodal Nasal NK/T Cell Lymphoma
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Oxaliplatin (this asset) | CStone Pharmaceuticals | P3 | BB · 65 |
| Pegaspargase | CStone Pharmaceuticals | P4 | BBB |
| Dexasone | Mingzhi Zhang | P4 | BBB |
| Cis-Diamminedichloroplatinum Ii | National Cancer Centre, Singapore | P4 | BBB |
| Etoposide | Tarapeutics Science Inc. | P4 | BB |
| Tucidinostat | Ruijin Hospital | P4 | BB |
| Lenalidomide | Xinhua Hospital, Shanghai Jiao Tong University School of Medicine | P4 | BB |
| Cediranib | Morphotek | P2 | BB |
| Asparaginase | National Cancer Centre, Singapore | P3 | BB |
+42 more in the Extranodal Nasal NK/T Cell Lymphoma cohort
Other indications for Oxaliplatin
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Exocrine Pancreatic Carcinoma | — | P2/3 | BBB · 76 |
| Colon Adenocarcinoma | — | P3 | BBB · 76 |
| Colorectal Neoplasm | — | P4 | BBB · 74 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Oxaliplatin in Extranodal Nasal NK/T Cell Lymphoma. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 13, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/oxaliplatin-extranodal-nasal-nkt-cell-lymphoma-27481
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →